Inflammatory and oxidative markers in atherosclerosis: Relationship to outcome

被引：59

作者：

Shishehbor M.H. ^{[1
]}

Hazen S.L. ^{[1
]}

机构：

[1] Department of Preventive Cardiology, Cleveland Clinic Foundation, Cleveland, OH 44195

来源：

Current Atherosclerosis Reports | 2004年 / 6卷 / 3期

关键词：

Acute Coronary Syndrome; Nitrotyrosine; Framingham Risk Score; Oxidative Marker; Soluble CD40 Ligand;

D O I：

10.1007/s11883-004-0038-1

中图分类号：

学科分类号：

摘要：

Inflammation and oxidative processes are key components of atherosclerosis, from fatty streak formation to plaque rupture and thrombosis. Recent basic and clinical studies have identified a number of inflammatory and oxidative processes that appear to play a direct role in atherothrombosis and identify potentially clinically useful markers of inflammation and oxidative stress. In this review, we highlight recent results on several of the more promising markers of inflammation for cardiovascular disease risk assessments, such as C-reactive protein, myeloperoxidase, and soluble CD40 ligand and nitrotyrosine, as well as other potential markers. Copyright © 2004 by Current Science Inc.

引用

页码：243 / 250

页数：7

共 76 条

[31]

Biasucci L.M., Liuzzo G., Colizzi C., Rizzello V., Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease, Ital. Heart J., 2, pp. 164-171, (2001)

[32]

Shishehbor M.H., Bhatt D.L., Topol E.J., Using C-reactive protein to assess cardiovascular disease risk, Cleve. Clin. J. Med., 70, pp. 634-640, (2003)

[33]

Ridker P.M., Cushman M., Stampfer M.J., Et al., Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men, N. Engl. J. Med., 336, pp. 973-979, (1997)

[34]

Kushner I., Sehgal A.R., Is high-sensitivity C-reactive protein an effective screening test for cardiovascular risk?, Arch. Intern. Med., 162, pp. 867-869, (2002)

[35]

Levinson S.S., Elin R.J., What is C-reactive protein telling us about coronary artery disease?, Arch. Intern. Med., 162, pp. 389-392, (2002)

[36]

Ridker P.M., Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial, Eur. Heart J., 22, pp. 2135-2137, (2001)

[37]

Schonbeck U., Libby P., CD40 signaling and plaque instability, Circ. Res., 89, pp. 1092-1103, (2001)

[38]

Henn V., Slupsky J.R., Grafe M., Et al., CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells, Nature, 391, pp. 591-594, (1998)

[39]

Schonbeck U., Mach F., Sukhova G.K., Et al., CD40 ligation induces tissue factor expression in human vascular smooth muscle cells, Am. J. Pathol., 156, pp. 7-14, (2000)

[40]

Aukrust P., Muller F., Ueland T., Et al., Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes, Circulation, 100, pp. 614-620, (1999)

← 1 2 3 4 5 6 7 8 →